Evidence mapPaperPMID 35291435Full record

Trial reportIranian journal of medical sciences2022

Co-Administration of Vitamin E and Atorvastatin Improves Insulin Sensitivity and Peroxisome Proliferator-Activated Receptor-γ Expression in Type 2 Diabetic Patients: A Randomized Double-Blind Clinical Trial.

Banafsheh Sadat Tabaei, Seyedeh Neda Mousavi, Aliasghar Rahimian, Hadi Rostamkhani, Ali Awsat Mellati, Maryam Jameshorani

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Iranian journal of medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Banafsheh Sadat TabaeiZanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
Seyedeh Neda MousaviZanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
Aliasghar RahimianDepartment of Clinical Biochemistry, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Hadi RostamkhaniDepartment of Clinical Biochemistry, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
Ali Awsat MellatiZanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.
Maryam JameshoraniZanjan Metabolic Diseases Research Center, Zanjan University of Medical Sciences, Zanjan, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Negative effects of statins on glucose metabolism have been reported. The present study aimed to investigate the effects of co-administration of vitamin E and atorvastatin on glycemic control in hyperlipidemic patients with type 2 diabetes mellitus (T2DM). Methods: A randomized double-blind clinical trial was conducted at Vali-e-Asr Teaching Hospital (Zanjan, Iran) from July 2017 to March 2018. A total of 30 T2DM female patients were allocated to two groups, namely atorvastatin with placebo (n=15) and atorvastatin with vitamin E (n=15). The patients received daily 20 mg atorvastatin and 400 IU vitamin E or placebo for 12 weeks. Anthropometric and biochemical measures were recorded pre- and post-intervention. Peroxisome proliferator-activated receptor-γ ( Results: After baseline adjustment, there was a significant improvement in homeostatic model assessment for insulin resistance (HOMA-IR) (P=0.04) and serum insulin (P<0.001) in the atorvastatin with vitamin E group compared to the atorvastatin with the placebo group. In addition, co-administration of vitamin E with atorvastatin significantly upregulated PPAR-γ expression (OR=5.4, P=0.04) in the PBMCs of T2DM patients. Conclusion: Co-administration of vitamin E and atorvastatin reduced insulin resistance and improved Trial registration number: IRCT 20170918036256N.

Indexed as

Diabetes Mellitus, Type 2Insulin ResistanceAtorvastatinDouble-Blind MethodFemaleHumansLeukocytes, MononuclearPPAR gammaVitamin EAtorvastatinPPAR gammaVitamin EAtorvastatinDiabetes mellitusInsulin resistancePeroxisome proliferator-activated receptorsVitamin E

Identifiers

PMID35291435
PMCPMC8919307

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.